Oliver Lagore Vanvalin Investment Group Has $29,000 Stock Holdings in CVS Health Co. (NYSE:CVS)

Oliver Lagore Vanvalin Investment Group lessened its holdings in CVS Health Co. (NYSE:CVS) by 70.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 366 shares of the pharmacy operator’s stock after selling 872 shares during the period. Oliver Lagore Vanvalin Investment Group’s holdings in CVS Health were worth $29,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of CVS. Moneta Group Investment Advisors LLC boosted its position in shares of CVS Health by 103,371.0% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 15,547,559 shares of the pharmacy operator’s stock worth $1,448,877,000 after buying an additional 15,532,533 shares during the period. Norges Bank acquired a new stake in shares of CVS Health in the fourth quarter worth $1,425,416,000. FMR LLC boosted its position in shares of CVS Health by 29.1% in the third quarter. FMR LLC now owns 27,487,238 shares of the pharmacy operator’s stock worth $1,919,159,000 after buying an additional 6,194,441 shares during the period. Morgan Stanley boosted its position in shares of CVS Health by 10.9% in the fourth quarter. Morgan Stanley now owns 33,576,388 shares of the pharmacy operator’s stock worth $3,128,984,000 after buying an additional 3,311,928 shares during the period. Finally, Barclays PLC boosted its position in shares of CVS Health by 97.8% in the second quarter. Barclays PLC now owns 5,483,154 shares of the pharmacy operator’s stock worth $379,052,000 after buying an additional 2,711,102 shares during the period. Institutional investors and hedge funds own 80.66% of the company’s stock.

Insider Transactions at CVS Health

In other news, EVP Prem S. Shah sold 29,473 shares of CVS Health stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $76.95, for a total value of $2,267,947.35. Following the transaction, the executive vice president now directly owns 39,765 shares in the company, valued at $3,059,916.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.24% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

CVS has been the subject of a number of research reports. HSBC initiated coverage on CVS Health in a research report on Friday, December 22nd. They set a “buy” rating and a $94.00 price objective for the company. Piper Sandler lifted their price objective on CVS Health from $93.00 to $94.00 and gave the company an “overweight” rating in a research report on Friday, March 15th. Barclays initiated coverage on CVS Health in a research report on Wednesday, March 6th. They set an “equal weight” rating and a $78.00 price objective for the company. StockNews.com cut CVS Health from a “buy” rating to a “hold” rating in a research report on Thursday, February 15th. Finally, Royal Bank of Canada reduced their price objective on CVS Health from $86.00 to $84.00 and set an “outperform” rating for the company in a research report on Thursday, February 8th. Four investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $89.44.

CVS Health Price Performance

NYSE CVS opened at $69.39 on Friday. The company has a debt-to-equity ratio of 0.77, a current ratio of 0.86 and a quick ratio of 0.63. The stock’s 50-day moving average is $75.42 and its two-hundred day moving average is $73.70. The firm has a market cap of $87.46 billion, a P/E ratio of 10.74, a price-to-earnings-growth ratio of 0.91 and a beta of 0.52. CVS Health Co. has a fifty-two week low of $64.41 and a fifty-two week high of $83.25.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Wednesday, February 7th. The pharmacy operator reported $2.12 EPS for the quarter, topping analysts’ consensus estimates of $2.01 by $0.11. The business had revenue of $93.81 billion for the quarter, compared to analyst estimates of $90.58 billion. CVS Health had a return on equity of 15.25% and a net margin of 2.33%. The firm’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same period in the previous year, the company posted $1.99 earnings per share. On average, analysts anticipate that CVS Health Co. will post 8.32 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Monday, April 22nd will be paid a $0.665 dividend. The ex-dividend date of this dividend is Friday, April 19th. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.83%. CVS Health’s payout ratio is presently 41.18%.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.